According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they''d opt for a shorter, healthier life than a longer one with health issuesDUBLIN, IRELAND / ACC…

Can this struggling healthcare specialist turn things around?

Although dividend investing has plenty of research backing its efficacy, it’s a slow burn. Further, it may incur high opportunity costs during broad-market rallies, such as what we saw during the bull in the Nasdaq last year. If one seeks capital appreciation potential, plan to sell some Dividend Aristocrats. Rather, invest in companies pursuing aggressive buyback activities, which could lead to significant short-term capital gains. The Dividend Aristocrats to sell in this list are marked with issues. Even well-established companies can see their competitive advantages erode over time. Closely examining the strength and durability of a company’s moat is crucial. In these case of these slow burners, one could seek better opportunities elsewhere. A prime example is investing in a buyback ETF like the Invesco BuyBack Achievers ETF (NASDAQ: PKW ), which has returned 61.76% over the past five years. So, let’s explore three dividend aristocrats to sell. Archer Daniels Midland (ADM) Source: Shutterstock A major player in the agricultural industry, Archer Daniels Midland (NYSE: ADM ) is known for processing grains and other products.

Medtronic, a healthcare technology company, shows promising growth with strong profitability and promising opportunities in diabetes care. Read more here.

No summary available.

https://www.investing.com/news/press-releases/cosmo-and-medtronic-unveil-the-future-of-ai-in-gi-genius-summit-2024-reveals-innovations-and-collaborations-that-advance-endoscopic-care-93CH-3376026

Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology,…

Cosmo Pharmaceuticals N.V. announces the launch of ColonPRO™ software, enhancing the GI Genius™ intelligent endoscopy system with improved AI-driven polyp detection and procedural highlights. Medtronic plc presents at the Genius Summit 2024, highlighting a new strategic collaboration with Cosmo and Modernizing Medicine® to enhance patient care. The GI Genius™ system has the potential to impact 2.7 million patients annually, with a 9% reduction in false positives due to the new software. The collaboration aims to streamline workflows, leverage augmented decision-making, and elevate the standard of care in endoscopic procedures.

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Medtronic (NYSE: MDT ). "I like what they’re doing in AI. You’ve got a good one with a good yield," he noted . On March 27, the FDA approved Medtronic’s Evolut FX+ transcatheter aortic valve replacement (TAVR) system for symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access. Riley Exploration Permian, Inc. … Full story available on Benzinga.com

AI-driven solutions and strategic alliances showcase Medtronic''s promise to enhance the efficiency and effectiveness of endoscopy DUBLIN, April 10, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial…